ES

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
Shift, Research, AD, Food, Medicare, FOCUS, Narcolepsy, Doctor of Philosophy, Fibromyalgia, Prescription, New Drug Application, Agitation, Shift work, Shirin David, Physician, SG, Acquisition, Smoking, Amgen, Webcast, Somnolence, NDA, Safety, Therapy, Patient, Food and Drug Administration, Central nervous system, Eli Lilly and Company, Reboxetine, SWD, ES, MD, Migraine, Growth, Binge eating disorder, Breakthrough therapy, Total, FDA, Government, SYMPHONY, CMC, CNS, R, DSM-IV codes, Horizon Therapeutics, BED, Dextromethorphan/bupropion, NMDA, Eating disorder, Beauty salon, Video game, Pharmaceutical industry, Bank, Dietary supplement, Solriamfetol, ADHD, Medicaid

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Key Points: 
  • “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.
  • Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023.
  • Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update.

Clean Harbors Announces Third-Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Recycling, Chemicals, Plastics, Environment, Oil, Gas, Manufacturing, Energy, Clean Harbors, NYSE, Eastman Kodak Co. v. Image Technical Services, Inc., Ecosystem, Incineration, Government, ES, EBITDA, GAAP, Acquisition, Field service management, CLH, Growth, Total Recordable Incident Rate, Harbor, PFAS, Maritime Industrial Services, CFO, Safety, SKSS, Collection, Video game, Bookkeeping, Renewable energy, Adjustment, Q4

Clean Harbors, Inc. (“Clean Harbors”) (NYSE: CLH), the leading provider of environmental and industrial services throughout North America, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Clean Harbors, Inc. (“Clean Harbors”) (NYSE: CLH), the leading provider of environmental and industrial services throughout North America, today announced financial results for the third quarter ended September 30, 2023.
  • This compared with net income of $135.8 million, or $2.50 per diluted share, for the same period in 2022.
  • In light of current market conditions and third-quarter results, for full-year 2023, Clean Harbors now expects:
    Adjusted EBITDA in the range of $1.005 billion to $1.025 billion or a midpoint of $1.015 billion.
  • Clean Harbors reports Adjusted EBITDA, which is a non-GAAP financial measure and should not be considered an alternative to net income or other measurements under generally accepted accounting principles (GAAP) but viewed only as a supplement to those measurements.

GS ENERGY Showcases Advanced Solar Storage Solutions at International Expos, Bolstering Global Expansion

Retrieved on: 
Thursday, October 26, 2023
Temperature, PV, ES, Solar, Cell, BMS, GS, Safety, Renewable energy

NINGBO, China, Oct. 26, 2023 /PRNewswire/ -- Recently, GS (Ningbo) ESS Technology Co., Ltd. (GS ENERGY), a global leader in smart energy solutions, showcased its residential photovoltaic (PV) storage-charging products and one-stop solutions at Solar & Storage Live UK and All-Energy Australia.

Key Points: 
  • NINGBO, China, Oct. 26, 2023 /PRNewswire/ -- Recently, GS (Ningbo) ESS Technology Co., Ltd. (GS ENERGY), a global leader in smart energy solutions, showcased its residential photovoltaic (PV) storage-charging products and one-stop solutions at Solar & Storage Live UK and All-Energy Australia.
  • GS ENERGY displayed an array of PV energy storage (ES) systems for diverse low voltage and high voltage applications alongside its industry-leading PV, ES and charging integration solution to customers and partners worldwide.
  • For flexibility, GS ENERGY solutions incorporate an intelligent battery management system (BMS) that automatically identifies the battery's position, simplifying future capacity expansion.
  • Leveraging these three advantages, GS ENERGY has garnered acclaim from customers in the UK, Australia and globally for the products and solutions showcased at Solar & Storage Live UK and All-Energy Australia.

GS ENERGY Showcases Advanced Solar Storage Solutions at International Expos, Bolstering Global Expansion

Retrieved on: 
Thursday, October 26, 2023
Temperature, PV, ES, Solar, Cell, BMS, GS, Safety, Renewable energy

NINGBO, China, Oct. 26, 2023 /PRNewswire/ -- Recently, GS (Ningbo) ESS Technology Co., Ltd. (GS ENERGY), a global leader in smart energy solutions, showcased its residential photovoltaic (PV) storage-charging products and one-stop solutions at Solar & Storage Live UK and All-Energy Australia.

Key Points: 
  • NINGBO, China, Oct. 26, 2023 /PRNewswire/ -- Recently, GS (Ningbo) ESS Technology Co., Ltd. (GS ENERGY), a global leader in smart energy solutions, showcased its residential photovoltaic (PV) storage-charging products and one-stop solutions at Solar & Storage Live UK and All-Energy Australia.
  • GS ENERGY displayed an array of PV energy storage (ES) systems for diverse low voltage and high voltage applications alongside its industry-leading PV, ES and charging integration solution to customers and partners worldwide.
  • For flexibility, GS ENERGY solutions incorporate an intelligent battery management system (BMS) that automatically identifies the battery's position, simplifying future capacity expansion.
  • Leveraging these three advantages, GS ENERGY has garnered acclaim from customers in the UK, Australia and globally for the products and solutions showcased at Solar & Storage Live UK and All-Energy Australia.

Press release - European elections 2024: MEPs’ proposals for the lead candidate system

Retrieved on: 
Thursday, October 26, 2023
Parliament, President of the European Council, Commission, Foundation, Council, Conference on the Future of Europe, European Commission, European Council, Treaty, Committee, EPP, DE, ES, State Affairs Commission of North Korea, Conference, S&D, Union, Civil service commission, Member of the European Parliament, Adoption, European Parliament Committee on Constitutional Affairs, European political party

They regret that recently proposed innovations for mobile citizens will not be applied in time for next year’s elections, as well as restrictions preventing European political parties from fully participating in European election campaigns.

Key Points: 
  • They regret that recently proposed innovations for mobile citizens will not be applied in time for next year’s elections, as well as restrictions preventing European political parties from fully participating in European election campaigns.
  • The report demands that democratic standards be applied when candidates are being nominated, including lead candidates for President of the European Commission.
  • The lead candidate system in 2024
    MEPs complain that the lead candidate system to elect the European Commission President was not applied in 2019 and insist that a clear and credible link between voters’ choice and this position is needed.
  • The lead candidate of the European political party with the most seats in Parliament should lead in the first round of negotiations, with Parliament’s President steering the process if needed.

Tecnoglass Announces Go to Market Strategy Milestone With Rebranding of ES Windows business to ES

Retrieved on: 
Friday, September 29, 2023
ES, TGLS, Growth, NYSE, History, BISU Visual Identity, Video game

Miami, Fl, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced a significant milestone for its ES Windows business.

Key Points: 
  • Miami, Fl, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced a significant milestone for its ES Windows business.
  • After decades of growth and success, ES Windows is embarking on a new journey, marked by the unveiling of its new corporate identity, transitioning from the former ES Windows brand to become ES.
  • This rebranding represents ES Windows's longstanding success and a strategic move to position the company for even greater achievements in the future.
  • Under ES’ leadership, the company has consistently created exceptional products that have solidified ES as one of the world's top window companies.

Eutelsat and Eurovision Services Sign New Long-term Partnership to Deliver Live Sports Events Over Europe and MENA

Retrieved on: 
Tuesday, September 19, 2023
Data Management, Satellite, Technology, Other Technology, Audio, Video, Telecommunications, Networks, Eutelsat, HD, Partnership, Internet, ES, Euronext Paris, Strategic management, Sport, ETL, UHD, Television, Entertainment, Eurovision Song Contest

This multi-year agreement enables Eurovision Services (ES) to support the live transmission of major sports events to audiences in Europe, the Middle East and North Africa, via Eutelsat’s fleet.

Key Points: 
  • This multi-year agreement enables Eurovision Services (ES) to support the live transmission of major sports events to audiences in Europe, the Middle East and North Africa, via Eutelsat’s fleet.
  • Eurovision Services underpins the global media content value chain, from in-venue content-capture and pop-up media control rooms, to rock-solid hybrid network capabilities—encompassing satellite, fibre, and internet.
  • ES services major sports federations, rights holders, and media companies to connect hundreds of millions of people to unmissable sports and events in HD and UHD resolution.
  • Professional video is an important market for Eutelsat and we ensure that our clients have the best services and capacity for their long-term needs.

Voyager Interests Adds Robert Trainer As Partner

Retrieved on: 
Monday, September 18, 2023
Other Energy, Oil, Gas, Coal, Finance, Alternative Energy, Energy, Professional Services, Nuclear, Trinity College, University, History, MBA, Simmons, Sale, ES, Simmons & Company International, Partner, Investment, Jan Vansina, NYSE, SLB, Voyager

Voyager Interests, LLC (“Voyager”), a specialized private equity firm focused on investments in the energy services and equipment ("ES&E") sector, today announced Robert Trainer has joined the firm as Partner.

Key Points: 
  • Voyager Interests, LLC (“Voyager”), a specialized private equity firm focused on investments in the energy services and equipment ("ES&E") sector, today announced Robert Trainer has joined the firm as Partner.
  • “Robert and I have worked together for almost two decades in a variety of capacities, most recently through his service on the Board of Directors of two Voyager portfolio companies,” said David Watson, Founder and Partner of Voyager.
  • “This deep working relationship is an ideal backdrop for his joining Voyager.
  • I am excited to partner with him.”
    Before joining Voyager, Robert Trainer was President & CEO of Gyrodata Incorporated, the worldwide leader in proprietary wellbore placement services, serving land and offshore markets.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.